We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+0.73%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$24.1B
AUM Growth
+$1.97B
Cap. Flow
+$2.05B
Cap. Flow %
8.49%
Top 10 Hldgs %
10.49%
Holding
3,709
New
1,118
Increased
953
Reduced
622
Closed
747

Sector Composition

Rank Sector Weight
1 Healthcare 20.28%
2 Financials 16.56%
3 Technology 13.74%
4 Consumer Discretionary 11.01%
5 Communication Services 4.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PDAC.WS
3651
CALL
DELISTED
Peridot Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Class A ordina
PDAC.WS
-365,208
Closed -$4.45M
PDAC
3652
DELISTED
Peridot Acquisition Corp.
PDAC
-328,161
Closed -$4M
HIMS.WS
3653
CALL
DELISTED
Hims & Hers Health, Inc. Warrants, each whole warrant exercisable for one Class A Common Stock at an
HIMS.WS
-83,332
Closed -$907K
GRSV
3654
DELISTED
Gores Holdings V, Inc.
GRSV
-1,499,990
Closed -$15.2M
GRSVW
3655
CALL
DELISTED
Gores Holdings V, Inc. Warrant
GRSVW
-299,998
Closed -$3.03M
TLND
3656
DELISTED
Talend S.A. American Depositary Shares
TLND
-93,181
Closed -$6.11M
VCVCW
3657
CALL
DELISTED
10X Capital Venture Acquisition Corp Warrant
VCVCW
-248,048
Closed -$2.47M
ALXN
3658
DELISTED
Alexion Pharmaceuticals
ALXN
-131,070
Closed -$24.1M
WORK
3659
DELISTED
Slack Technologies, Inc.
WORK
-653,036
Closed -$28.9M
CNST
3660
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
-66,135
Closed -$2.23M
ALUS
3661
DELISTED
Alussa Energy Acquisition Corp
ALUS
-524,005
Closed -$5.19M
CCRC
3662
DELISTED
China Customer Relations Centers, Inc
CCRC
-115,669
Closed -$751K
WPF.WS
3663
CALL
DELISTED
Foley Trasimene Acquisition Corp. Warrants, each whole warrant exercisable for one share of Class A
WPF.WS
-83,327
Closed -$814K
WTRE
3664
DELISTED
Watford Holdings Ltd. Common Shares
WTRE
-14,233
Closed -$498K
PRAH
3665
DELISTED
PRA Health Sciences, Inc.
PRAH
-134,119
Closed -$22.2M
NAV
3666
DELISTED
Navistar International
NAV
-21,459
Closed -$955K
CCMP
3667
DELISTED
CMC Materials, Inc. Common Stock
CCMP
-14,900
Closed -$2.25M
CFRX
3668
DELISTED
ContraFect Corporation
CFRX
-649
Closed -$229K
VISL
3669
DELISTED
Vislink Technologies, Inc. Common Stock
VISL
-7,444
Closed -$424K
GTYH
3670
DELISTED
GTY Technology Holdings, Inc. Common Stock
GTYH
-15,260
Closed -$108K
MACK
3671
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
-39,150
Closed -$250K
COWN
3672
DELISTED
Cowen Inc. Class A Common Stock
COWN
-22,980
Closed -$943K
EGLE
3673
DELISTED
Eagle Bulk Shipping Inc.
EGLE
-42,240
Closed -$2M
SIVB
3674
DELISTED
SVB Financial Group
SIVB
-8,000
Closed -$4.45M
ATIP
3675
DELISTED
ATI Physical Therapy, Inc.
ATIP
-10,172
Closed -$4.85M

Similar funds

Marshall Wace's Q3 2021 Portfolio in Review

As of Q3 2021, Marshall Wace held 3,709 positions worth $24.1B, up 8.9% from $22.1B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Marshall Wace deployed $2.05B of net new capital in Q3 2021, opening 1,118 new positions and adding to 953 existing holdings. Its largest new stake was SkinHealth Systems: 4,113,430 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Biogen, an estimated $210M trimmed.

  • Marshall Wace's largest Q3 2021 buy was SkinHealth Systems: 4,113,430 shares worth $107M.
  • Marshall Wace added most to Uber in Q3 2021, an estimated $127M increase.
  • Marshall Wace's biggest Q3 2021 reduction was Biogen, cutting an estimated $210M.
  • Marshall Wace fully exited Vipshop in Q3 2021, selling an estimated $58.7M.
  • Marshall Wace's ten largest holdings make up 10% of its $24.1B portfolio in Q3 2021.
  • Marshall Wace opened 1,118 new positions and closed 747 in Q3 2021.
  • Marshall Wace's portfolio value rose 8.9% quarter-over-quarter to $24.1B.

Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.